BCL2 and breast cancer: In addition, treatment with rPGC1α (40 ng/mL) significantly reduced the levels of apoptosis markers (BAX, cytochrome c, caspase-9, cleaved caspase-9, and caspase-3) and increased Bcl-2 and PARP1 expression in both the BC cell lines (Figure 5A,B).